Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.

Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.

Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace Directory

Laboratory analyzer workflow interface, 9/13

The IVD Industry Connectivity Consortium (IICC) has developed a laboratory analyzer workflow (LAW) interface, which is a global interface based on a common set of clinical laboratory communications that unambiguously define communication protocols. In 2012, four diagnostic and three IT companies successfully validated 129 LAW tests. Since then, IICC has refined these interfaces and is asking more manufacturers to adopt the standard in an effort to simplify connectivity in the clinical laboratory and within the health care enterprise. Benefits of

Reference solutions for bath salt metabolites, 9/13

Cerilliant offers seven new certified spiking solutions of bath salt metabolites. The new products are 1.0 mg/mL (as free base) in methanol for the primary urinary metabolites of bath salt cathinones, mephedrone, buphedrone, pentedrone, flephedrone, N-ethylcathinone, and 4-methylethcathinone. For GC/MS and LC/MS methods that quantify concentrations of synthetic cathinone metabolites, the company also offers the corresponding deuterium-labeled internal standard. Cerilliant offers certified Snap-N-Spike solutions for use in clinical toxicology applications, medication monitoring, forensic analysis, employee drug screening, and urine drug

Reference solutions for thyroid hormones, 9/13

Cerilliant offers certified Snap-N-Spike solutions of thyroid hormones T4, T3, and reverse T3 at concentrations of 100 µg/mL in 0.1 N ammonia in methanol for each solution standard. These certified spiking solutions are for use as critical starting materials in the preparation of calibrators, controls, or linearity standards for analytical testing including LC-MS/MS analysis of free and total thyroid hormone levels. Comprehensive certificates of analysis (COAs) come with every Cerilliant certified reference standard and include all analytical data from full

Sanger sequencing system and HLA typing kits, 9/13

Life Technologies in February received FDA 510(k) clearance for its 3500 Dx genetic analyzers and SeCore HLA typing kits. The company’s 7500 Fast Dx real-time PCR system was cleared for diagnostic use with the CDC’s H1N1 assay in 2008. The Applied Biosystems 3500 Dx/3500xL Dx CS2 genetic analyzers, Invitrogen SeCore HLA sequencing kits, and uType Dx HLA sequence analysis software constitute the first FDA 510(k)-cleared sequence-based system for HLA typing in the United States. HLA typing on the 3500 Dx

General-purpose reagents, 9/13:80 (AACC)

NanoString Technologies’ nCounter Elements are digital molecular bar-coding chemistry assay components that allow users to assemble their own assays with oligonucleotide probes that target their genes of interest. The components enable highly multiplexed, direct profiling of individual molecules in a single reaction without amplification and are effective for a range of applications requiring efficient, high-precision quantitation of tens to hundreds of target molecules across a sample set. This chemistry generates high-quality results from challenging sample types, such as FFPE tissue

C. diff assay and PCR system, 9/13:78 (AACC)

Quidel Corp. and Life Technologies in March received FDA 510(k) clearances to market the Quidel Molecular Direct C. difficile assay with Life Technologies’ QuantStudio Dx and 7500 Fast Dx Applied Biosystems real-time PCR instruments. The C. difficile assay is part of Quidel’s molecular diagnostic product line, which includes PCR reagent kits for molecular diagnostic laboratories including Life Technologies’ QuantStudio Dx and 7500 Fast Dx. These reagents can be refrigerated instead of frozen, are convenient and ready to use, and provide a

NGS analytics software, 9/13:78 (AACC)

Life Technologies’ Oncomine Next-Gen Sequencing Power Tools is an analytics offering that will allow cancer researchers to explore results from in-depth analysis of next-generation sequencing (NGS) data, including data from The Cancer Genome Atlas. In total, more than 4,500 paired tumor and samples have been analyzed. Oncomine NGS Power Tools constitute a suite of software tools that enable cancer researchers to easily survey novel predicted driver mutations and gene fusions across all cancers and within two dozen specific cancer types,

Automated ESR analysis system, 9/13:78 (AACC)

Through a distribution agreement with Alifax, Beckman Coulter and Iris Diagnostics have launched the Alifax automated erythrocyte sedimentation rate (ESR) analysis system. The automated ESR analysis systems are designed to fit the workloads of small hospitals, large reference laboratories, core laboratories, and satellite locations. The ESR system increases productivity, improves efficiencies in laboratory labor use, and reduces turnaround times. The Alifax ESR system provides fully automated, hands-off operation in a small footprint and processes the same whole blood tubes from

HbA1c test, 9/13 (AACC)

Beckman Coulter’s FDA-approved hemoglobin A1c assay (HbA1c) with improved performance is for standard use on the company’s UniCel DxC systems. The HbA1c reagent was designed and developed to improve accuracy and precision, to continue to meet the latest accuracy grading from the College of American Pathologists and the recommendations of the National Glycohemoglobin Standardization Program and International Federation of Clinical Chemistry. The assay features ready-to-use liquid reagents for A1c and total hemoglobin; a five-level calibrator set; 30-day onboard reagent stability;

Troponin I assay, 9/13:76 (AACC)

Beckman Coulter’s FDA-cleared Access AccuTnI+3 troponin I assay is available for use on the company’s Access 2 immunoassay system. In accordance with FDA requirements, the company conducted a large multicenter prospective clinical trial on the AccuTnI+3 troponin I assay that enrolled more than 1,900 subjects. The trial confirmed that the assay provides the clinical performance necessary for optimal patient management. The data from the trial show that the assay delivers the precision, clinical sensitivity, and clinical specificity necessary to assist

MARKETPLACE

TRENDING